All studies
Phase 3RecruitingInterventionalNCT07829653

A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through Menopause

A Phase 3, Single-arm, 12-week Study to Assess the Efficacy and Safety of Fezolinetant 45 mg in Indian Women Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause

  • Hot Flashes
I want to take partRefer a patient1 site in India · 1 worldwide

At a glance

Phase
Phase 3
Study type
Interventional
Sponsor
Astellas Pharma Inc
Enrolment target
100
Started
23 October 2026
Main results due (estimated)
31 March 2028
Study ends (estimated)
30 April 2028
Allocation
Na
Design
Single group
Purpose
Treatment
Masking
None
Sites
1 · 1 in India
First posted
21 September 2026
Registry updated
2 November 2026

Can you take part?

  • Aged 18 years and over.
  • Women only.
  • You need the condition being studied. Healthy volunteers are not accepted.

Age groups: adult, older adult.

These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.

Read the full eligibility criteria
Inclusion Criteria:

* Participant has a body mass index ≥ 17 kg/m\^2 and ≤ 38 kg/m\^2 at screening visit.
* Participant must be seeking treatment or relief for VMS associated with menopause and confirmed as menopausal, defined as meeting 1 of the following criteria for natural or surgical menopause at the screening visit:

  * Spontaneous amenorrhea for ≥ 12 consecutive months
  * Spontaneous amenorrhea for ≥ 6 months with biochemical criteria of menopause (FSH \> 40 IU/L); or
  * Having had bilateral oophorectomy ≥ 6 weeks prior to the screening visit (with or without hysterectomy).
  * FSH \> 40 IU/L if participants received hysterectomy but still have an ovary/ovaries.
* Within the 10 days prior to start of active treatment, participant must have a minimum average of 7 moderate to severe hot flashs (VMS) per day (data must be available for at least 7 of the last 10 days prior to treatment).
* Participant is in good general health as determined on the basis of medical history and general physical examination, performed at the screening visit; hematology and biochemistry parameters, pulse rate and/or blood pressure, and ECG within the reference range for the population studied, or showing no clinically relevant deviations.
* Participant has a negative urine pregnancy test at screening; this is not required for participants who have had a total hysterectomy.
* Participant has a negative serology panel (i.e., negative hepatitis B surface antigen \[HBsAg\], negative hepatitis C virus antibody \[HCVAb\] and negative human immunodeficiency virus antibody \[HIVAb\] screens) at screening.
* Participant agrees not to participate in another interventional study while participating in the present study.

Exclusion Criteria:

* Participant has known substance abuse or alcohol addiction within 6 months of screening.
* Participant has a history of malignancy with the exception of at least 5 years post treatment and without known recurrence.
* Participant has a current malignancy, with the exception of non-metastatic basal cell carcinoma of the skin.
* Participant has a history within the last 6 months prior to screening of undiagnosed uterine bleeding.
* Participant has a medical condition or chronic disease (including history of neurological \[including cognitive\], hepatic, renal, cardiovascular, gastrointestinal, pulmonary \[e.g., moderate asthma\], endocrine, or gynecological disease) or malignancy that could confound interpretation of the study outcome.
* Participant has a history of suicide attempt or suicidal behavior within the last 12 months or has suicidal ideation within the last 12 months, or who is at significant risk to commit suicide.
* Participant has previously been enrolled in a clinical trial with fezolinetant or other neurokinin (NK) receptor antagonists.
* Participant uses a prohibited therapy (strong and moderate CYP \[cytochrome P450\] 1A2 inhibitors, systemic hormone replacement therapy \[HRT\], or hormonal contraceptive, or any treatment for VMS \[prescription, over the counter, off-label or herbal\]) or is not willing to wash-out and discontinue use of such drugs for the full duration of study conduct.
* Participant has received any investigational therapy within 35 days or 5 half-lives, whichever is longer, prior to screening.
* Participant has uncontrolled hypertension defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure as ≥ 90 mmHg based on an average of 2 to 3 readings within the screening period.

  * Participants with a medical history of hypertension who are well controlled may be enrolled.
  * Participants who do not meet these criteria may be re-assessed after initiation or review of antihypertensive measures.
* Participant has active liver disease, jaundice, elevated liver aminotransferases (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\]), elevated total bilirubin (TBL) or direct bilirubin (DBL), elevated international normalized ratio (INR) or elevated alkaline phosphatase (ALP). Patients with mildly elevated ALT or AST up to 1.5 x upper limit of normal (ULN) can be enrolled if TBL are normal. Patients with mildly elevated ALP (up to 1.5 x ULN) can be enrolled if cholestatic liver disease is excluded and no cause other than fatty liver is diagnosed. Patients with Gilbert's syndrome with elevated TBL may be enrolled as long as hemolysis is ruled-out (i.e., DBL, hemoglobin and reticulocytes are normal).
* Participant has creatinine \> 1.5 × ULN; or estimated glomerular filtration rate using the Modification of Diet in Renal Disease formula ≤ 30 mL/min per 1.73 m\^2 at screening.
* Participant has any condition which makes the participant unsuitable for study participation.
* Participant has known or suspected hypersensitivity to fezolinetant or any components of the formulation used.
* Participant is unable or unwilling to complete the study procedures.

What this study is about

In the sponsor’s own words, from the registry.

This study is for women in India who are going through menopause. They have symptoms including hot flashes and night sweats (also known as vasomotor symptoms or VMS). Fezolinetant is a medicine to treat hot flashes in women going through menopause. It is currently approved in more than 40 countries, including the US and countries in Europe. Further studies are needed before it is approved for use in India. The aim of this study is to confirm if fezolinetant can help reduce hot flashes in Indian women. Women who want to take part in the study will be given an electronic device or use the app on their own smartphone to track their hot flashes and night sweats. The women will record this information before, during and after taking the study treatment. All the women in the study will take 1 tablet of fezolinetant once a day for up to 12 weeks. During the study, the women will visit the study clinic several times. The researchers will collect information about the women's health and ask about their hot flashes and night sweats. At each visit, they will also be asked if they have any medical problems. The women will have a follow up visit 3 weeks after taking their last tablet of study treatment, to collect information about their health and symptoms. Each woman will be in this study for about 5 months.

Keywords: menopause · vasomotor symptoms · ESN364 · fezolinetant · VEOZAH™

What participants receive

  • Experimental

    Fezolinetant

    Participants will receive fezolinetant once daily for 12 weeks.

    Drug: Fezolinetant

Interventions

  • FezolinetantDrug

    Also known as ESN364, VEOZAH™

    Oral

What the study measures

Primary outcomes

  1. Mean change from baseline in the frequency of moderate to severe vasomotor symptoms (VMS)

    Frequency of moderate and severe VMS events will be calculated as sum of moderate and severe VMS events per day.

    Time frame: Baseline and week 12

Secondary outcomes

  1. Mean change from baseline in the frequency of moderate to severe VMS

    Frequency of moderate and severe VMS events will be calculated as sum of moderate and severe VMS events per day.

    Time frame: Baseline and up to week 12

  2. Mean change from baseline in the severity of moderate to severe VMS

    The severity of VMS will be calculated using a weighted average of VMS events.

    Time frame: Baseline and up to week 12

  3. Mean percent reduction in the frequency of moderate to severe VMS

    Frequency of moderate or severe VMS events will be calculated as the sum of moderate or severe VMS events per day. Mean percent reduction will be reported.

    Time frame: Baseline and up to week 12

  4. Percent reduction ≥ 50% in the frequency of moderate to severe VMS

    Frequency of moderate and severe VMS events will be calculated as the sum of moderate or severe VMS events per day. Percent reduction of ≥ 50% will be reported.

    Time frame: Baseline and up to week 12

  5. Percent reduction of 100% in the frequency of moderate to severe VMS

    Frequency of moderate and severe VMS events will be calculated as the sum of moderate or severe VMS events per day. Percent reduction of 100% will be reported.

    Time frame: Baseline and up to week 12

  6. Number of participants with adverse events (AEs)

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to week 15

  7. Number of participants with laboratory value abnormalities and/or AEs

    Number of participants with potentially clinical significant laboratory values.

    Time frame: Up to week 15

  8. Number of participants with vital sign abnormalities and/or AEs

    Number of participants with potentially clinical significant vital sign values.

    Time frame: Up to week 15

  9. Number of participants with electrocardiogram (ECG) abnormalities and/or AEs

    Number of participants with potentially clinical significant ECG values.

    Time frame: Up to week 12

  10. Pharmacokinetics (PK) of fezolinetant in plasma: Concentration

    Concentration will be recorded from the PK plasma samples.

    Time frame: Up to week 12

  11. PK of metabolite ES259564 in plasma: Concentration

    Concentration will be recorded from the PK plasma samples.

    Time frame: Up to week 12

  12. Change in serum concentrations of sex hormones: luteinizing hormone (LH)

    Concentration will be recorded from pharmacodynamics serum samples.

    Time frame: Baseline and up to Week 15

  13. Change in serum concentrations of sex hormone: follicle-stimulating hormone (FSH)

    Concentration will be recorded from pharmacodynamics serum samples.

    Time frame: Baseline and up to Week 15

  14. Change in serum concentrations of sex hormone: estradiol (E2)

    Concentration will be recorded from pharmacodynamics serum samples.

    Time frame: Baseline and up to Week 15

  15. Change in serum concentrations of sex hormone: testosterone

    Concentration will be recorded from pharmacodynamics serum samples.

    Time frame: Baseline and up to Week 15

  16. Change in serum concentrations of sex hormone-binding globulin (SHBG)

    Concentration will be recorded from pharmacodynamics serum samples.

    Time frame: Baseline and up to Week 15

Who is running it

Lead sponsor
Astellas Pharma Inc
Sponsor type
Industry
Responsible party
The sponsor
Organisation
Astellas Pharma Inc
Data monitoring committee
No
US FDA-regulated drug
No
US FDA-regulated device
No
Sponsor's study ID
2693-CL-0315
  • Associate Mecial Director

    Study director

    Astellas Pharma Global Development, Inc.

Study sites(1)

  • Site IN91011

    Bengaluru, Karnataka, India

    Recruiting

Showing 1 of 1 sites. 1 recruiting, 0 not recruiting and 0 cancelled; 1 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.

References and data sharing

Participant data shared
Yes
What is shared
Study protocol, Sap, Csr
When
Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
Access
Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Source: ClinicalTrials.gov record NCT07829653, status verified October 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Take part

Interested in this study?

Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.

A person reads this, not a bot. We are not doctors, this is not medical advice, and it is not for emergencies.

Not the right study?

Every study recruiting in India, one search away.